Details

Autor(en) / Beteiligte

• De Klaver, Paul A. G.
• Geesink, Carolien M.
• Broen, Jasper C. A.
• Derijks, Luc J. J.

Titel

Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report

Ist Teil von

• Clinical drug investigation, 2022-09, Vol.42 (9), p.787-789

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Leflunomide is a prodrug for teriflunomide, an inhibitor of pyrimidine synthesis. It is used for treatment of rheumatic diseases [1]. Teriflunomide inhibits dihydroorotate dehydrogenase (DHODH), which mediates synthesis of the pyrimidine ribonucleotide uridine monophosphate (rUMP). DHODH-dependent rUMP synthesis is required for activation of lymphocytes. As a result, leflunomide can inhibit autoimmune T-cell proliferation and production of autoantibodies by B cells [2]. Here we describe an unintended pregnancy during leflunomide use. We describe washout procedures, serum teriflunomide concentrations and pregnancy outcome in this report.